Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer

AbstractResistance to chemotherapy is widely recognized as one of the major factors limiting therapeutic efficacy and influences clinical outcomes in patients with cancer. Many studies on various tumor types have focused on combining standard-of-care chemotherapy with immunotherapy. However, for cervical cancer, the role of neoadjuvant chemotherapy (NACT) on the local immune microenvironment is largely unexplored. We performed a pilot study on 13 primary cervical tumor samples, before and after NACT, to phenotype and enumerate tumor-infiltrating T-cell subpopulations using multiplex immunohistochemistry (CD3, CD8, FoxP3, Ki67, and Tbet) and automated co-expression analysis software. A significant decrease in proliferating (Ki67+) CD3+CD8− T cells and FoxP3+(CD3+CD8−) regulatory T cells was observed in the tumor stroma after cisplatin and paclitaxel treatment, with increased rates of cytotoxic CD8+ T cells, including activated and CD8+Tbet+ T cells. No effect was observed on the number of tumor-infiltrating T cells in the cervical tumor microenvironment after treatment with cisplatin only. Therefore, we conclude that  patients treated with cisplatin and paclitaxel had more tumor-infiltrating T-cell modulation than patients treated with cisplatin monotherapy. These findings enhance our understanding of the immune-modulating effect of chemotherapy and warrant future combination of the standard-of-care therapy wit h immunotherapy to improve clinical outcome in pa...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research

Related Links:

(Elsevier) A new study in The American Journal of Pathology, published by Elsevier, reports that medroxyprogesterone acetate (MPA), the active ingredient in the common contraceptive injection Depo-Provera, was effective in preventing the development of cervical cancer in mice with precancerous lesions. The drug also decreased existing precancerous lesions. If proven effective clinically, MPA may be a boon to women who do not have access to human papillomavirus (HPV) vaccines.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Mailing self-sampling kits to test for the cervical cancer-causing virus HPV significantly increased screening rates for the cancer, according to a new study.
Source: WebMD Health - Category: Consumer Health News Source Type: news
[UCT] Cape Town -University of Cape Town (UCT) Professor Lynette Denny's 25-year body of research on cervical cancer, which affects 80% of black women in South Africa, has won a prestigious South African Medical Research Council (SAMRC) Gold Medal in its golden jubilee year.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Title: Self-Testing for Cervical Cancer Increases Screening RatesCategory: Health NewsCreated: 11/8/2019 12:00:00 AMLast Editorial Review: 11/11/2019 12:00:00 AM
Source: MedicineNet Cancer General - Category: Cancer & Oncology Source Type: news
In Ethiopia, most cervical cancer patients present at advanced cancer stages, long time after they experience first symptoms. We investigated possible predictors of long time spans between symptom onset and pa...
Source: Infectious Agents and Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
High-risk human papillomavirus (HR-HPV) testing is more sensitive than cytology for the detection of cervical cancer and its precursors. However, limited and inconsistent data are available about the efficacy ...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Research article Source Type: research
Discussion and conclusionThe Authors, as a result of the present study, suggest that office hysteroscopy should be sussessful at the first attempt, because the majority of patients (58%), in case of a failed procedure, do not undergo a repeat hysteroscopy in a reasonable time and important diagnosis, such as that of endometrial cancer, may be missed or delayed. In order to increase the procedure success rate, prior to the scheduled hysteroscopy they recommend to counsel all patients, identifying those who may benefit from pharmacological cervical softening, local anesthetic injection or the use of small caliber hysteroscopes.
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
Authors: Pimple SA, Mishra GA Abstract Disparities in the incidence and mortality due to cervical cancer between developed and developing countries continue to persist due to suboptimal health care systems in low- to middle-income countries (LMICs) that are unable to implement organized programs for screening which lack the technical, infrastructure and financial resources for adequate coverage and access to quality assured cervical cancer screening services that further reduce their effectiveness. The challenges in introducing quality cytology screening in LMICs led to the evaluation of alternative screening appro...
Source: Minerva Ginecologica - Category: OBGYN Tags: Minerva Ginecol Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study